Dr. Neyssa Marina, MD
Palo Alto, CA
Who is Dr. Marina, Pediatric Hematologist-Oncologist in Palo Alto, CA?
Dr. Neyssa Marina, MD is a Pediatric Hematologist-Oncologist, who primarily practices in Palo Alto, CA. She is board certified. Dr. Marina graduated from University of Puerto Rico, School of Medicine and completed her residency at University Pediatric Hospital, Puerto Rico. Dr. Marina is fluent in English and Spanish, and is currently seeing new patients. To book an appointment or to confirm insurance options, please call Dr. Marina’s office at (650) 497-8953.
What are Areas of Expertise for Dr. Marina?
Dr. Neyssa Marina, MD is a highly-rated, board-certified Pediatric Hematologist-Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Marina empowers patients to confidently navigate their health journey, specializing in Cancer Survivors-Late Effects of Therapy, Sarcoma, Sarcoma-Soft Tissue, and comprehensive wellness support. Serving the Palo Alto, CA community, Dr. Marina is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Marina go to medical school and complete their residency?
Fellowship: St Jude Children's Research Hospital, Memphis, TN | St Jude Children's Research Hospital TN | St. Jude Children's Hospital Pediatric Hematology-Oncology | St Jude Children's Research Hospital
Residency: University Pediatric Hospital, Puerto Rico | UNIVERSITY PEDIATRIC HOSPITAL
Medical School: University of Puerto Rico, School of Medicine
Is Dr. Marina board certified as a Pediatric Hematologist-Oncologist?
Yes, Dr. Neyssa Marina, MD is board certified by the American Board of Pediatrics , American Board of Pediatrics since 1990, American Board of Dermatology since 1990
What languages does Dr. Marina speak?
Dr. Marina and their clinical team can communicate with patients in the following languages:
English
Spanish
What conditions does a Pediatric Hematologist-Oncologist like Dr. Marina typically treat?
As a Pediatric Hematologist-Oncologist, conditions treated by Dr. Neyssa Marina may include:
Please contact Dr. Marina's office directly to confirm care for your specific condition, for more information, or to schedule a consultation.
What procedures does a Pediatric Hematologist-Oncologist like Dr. Marina typically perform?
As a Pediatric Hematologist-Oncologist, procedures performed by Dr. Neyssa Marina may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
Please contact Dr. Marina's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Marina accept my insurance?
Please contact Dr. Marina's office to confirm accepted insurance plans.
Where is Dr. Marina's office located?
Recognitions
Awards
Alfa Omega Alfa Honor Society, Alfa Omega Alfa
Phi Kappa Phi Honor Society, Phi Kappa Phi
Magna Cum Laude-Antoine Lavoiser Chemistry Award,
University of PR, Mayaguez Campus
Publications
Feasibility and dose discovery alysis of zoledronic acid with concurrent chemotherapy in the
, 2013
Pediatric Acute Myeloid Leukemia as Classified Using 2008 WHO Criteria: A Single-Center Experience.
, 2013
A pilot study of low-dose anti-angiogenic chemotherapy in combition with st
, 2013
Genome-wide association study identifies two susceptibility loci for osteosarcoma.
Phase II Trial of Trastuzumab in Combition With Cytotoxic Chemotherapy
, 2012
Symptom Cluster Alyses Based on Symptom Occurrence
, 2012
Changes in Children's Reports of Symptom Occurrence
, 2010
Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmory Recurrence of
, 2010
Current Treatment Protocols Have Elimited the Prognostic Advantage of Type 1 Fusions
, 2010
Multiple Symptoms in Pediatric Oncology Patients: A Systematic Review
, 2009
Dose-Intensified Compared With St
, 2009
Physical Performance Limitations in the Childhood Cancer Survivor Study Cohort
, 2009
Intertiol Collaboration is Feasible in Trials for Rare Conditions: The EURAMOS Experience
, 2009
Rel function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy
, 2009
Second Solid Maligncies Among Children, Adolescents
, 2008
Osteosarcoma: The same old drugs or more?
, 2008
Application of the adult Intertiol Germ Cell Classification system to pediatric malignt non
, 2008
Complementary and altertive therapy use in adult survivors of childhood cancer
, 2008
Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors
, 2007
Chronic health conditions in adult survivors of childhood cancer
, 2006
Prognostic factors in children with extragodal malignt germ cell tumors
, 2006
High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remission
, 2005
Development of risk-based guidelines for pediatric cancer survivors
, 2004
Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignt
, 2004
Randomized comparison of combition chemotherapy with etoposide, bleomycin
, 2004
Health status of adult long-term survivors of childhood cancer
, 2003
Carboplatin/ifosfamide window therapy for osteosarcoma
, 2001
Acute lymphoblastic leukemia in a developing country
, 2000
Abnormalities of the thyroid in survivors of Hodgkin's disease
, 2000
Hematologic abnormalities and acute myeloid leukemia
, 2000
Comparative rel tubular toxicity of chemotherapy regimens including ifosfamide
, 2000
Surgical resection alone is effective treatment for ovarian immature teratoma in children
, 1999
Complete surgical excision is effective treatment for children with immature teratom
, 1999
Late effects of treatment for germ cell tumors during childhood and adolescence
, 1999
Biology and therapy of pediatric malignt solid tumors.
, 1999
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors
, 1999
Nongestatiol choriocarcinoma in the postpartum period: A case report
, 1998
Comparison of cytokines in children with recurrent solid tumors treated with intensive chemotherapy
, 1998
Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor
, 1998
Phase I trial of subcutaneous interleukin-1 alpha in children with malignt solid tumors
, 1997
Biology and treatment of pediatric malignt solid tumors.
, 1997
Local control in synchronous bilateral Wilms tumor
, 1996
Response of pediatric malignt solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide
, 1996
St Jude Children's Research Hospital's intertiol outreach program
, 1996
Cytomegalovirus causing pericarditis with tampode in an adolescent with cancer
, 1996
SERIAL PULMORY-FUNCTION STUDIES IN CHILDREN TREATED FOR NEWLY
, 1995
A PHASE-I STUDY OF SULOFENUR IN REFRACTORY PEDIATRIC MALIGNT SOLID TUMORS
, 1995
REFINING THERAPEUTIC STRATEGIES FOR PATIENTS WITH RESISTANT WILMS-TUMOR
, 1994
RESPONSE OF IMMUNOCOMPROMISED CHILDREN WITH SOLID TUMORS TO A CONJUGATE VACCINE FOR HAEMOPHILUS
, 1994
LACK OF HERITABILITY IN OVARIAN GERM-CELL MALIGNCIES
, 1994
PHASE-I STUDY OF ESCALATING TARGETED DOSES OF CARBOPLATIN COMBINED WITH IFOSFAMIDE AND ETOPOSIDE IN
, 1994
PHASE-I STUDY OF TOPOTECAN FOR PEDIATRIC-PATIENTS WITH MALIGNT SOLID TUMORS
, 1994
PRIMARY MALIGNCY OF THE SALIVARY-GLAND IN CHILDREN
, 1994
A PHASE-I STUDY OF IFOSFAMIDE WITH MES GIVEN DAILY FOR 3 CONSECUTIVE DAYS TO CHILDREN WITH MALIGNT
, 1993
ACUTE HYPERSENSITIVITY REACTIONS TO ETOPOSIDE IN A VEPA REGIMEN FOR HODGKINS-DISEASE
, 1993
PROGRESS IN THE TREATMENT OF ADOLESCENTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA
, 1993
PHASE-I STUDY OF ESCALATING TARGETED DOSES OF CARBOPLATIN COMBINED WITH IFOSFAMIDE AND ETOPOSIDE IN
, 1993
EFFICACY AND TOXICITY OF MULTIAGENT CHEMOTHERAPY AND LOW-DOSE INVOLVED
, 1993
IFOSFAMIDE PLUS ETOPOSIDE IN NEWLY DIAGNOSED EWINGS-SARCOMA OF BONE
, 1992
THE ROLE OF 2ND-LOOK SURGERY IN THE MAGEMENT OF ADVANCED GERM-CELL MALIGNCIES
, 1991
EFFECT OF NUCLEOSIDE TRANSPORT INHIBITORS ON THYMIDINE SALVAGE
, 1991
USE OF MR IMAGING TO ASSESS RESULTS OF CHEMOTHERAPY FOR EWING SARCOMA
, 1990
Comparison of Latino and Non-Latino Patients With Ewing Sarcoma
, 2014
Pilot study of cisplatin, etoposide
, 2013
Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the
, 2013
Children's Oncology Group's 2013 blueprint for research: Bone tumors.
, 2013
Changes in health status among aging survivors of pediatric upper and lower extremity sarcoma
, 2013
Pediatric Acute Myeloid Leukemia as Classified Using 2008 WHO Criteria: A Single-Center Experience.
, 2013
A pilot study of low-dose anti-angiogenic chemotherapy in combination with st
, 2013
Genome-wide association study identifies two susceptibility loci for osteosarcoma.
Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma
, 2012
Outcome for adolescent and young adult patients with osteosarcoma
, 2012
Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy
, 2012
Symptom Cluster Analyses Based on Symptom Occurrence
, 2012
Body Mass Index (BMI) at Diagnosis Is Associated With Surgical Wound Complications in Patients With
, 2011
High-Intensity Focused Ultrasound (HIFU) Is Not Indicated for Treatment of Primary Bone Sarcomas
, 2011
An evaluation of the factors that affect the health
, 2011
Twenty Years of Follow-Up of Survivors of Childhood Osteosarcoma
, 2011
Changes in Children's Reports of Symptom Occurrence
, 2010
Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of
, 2010
Current Treatment Protocols Have Eliminated the Prognostic Advantage of Type 1 Fusions
, 2010
The Role of Interferons in the Treatment of Osteosarcoma
, 2010
Knowledge of Hepatitis C Virus Screening in Long
, 2010
Angiogenesis and Vascular Targeting in Ewing Sarcoma A Review of Preclinical and Clinical Data
, 2010
Multiple Symptoms in Pediatric Oncology Patients: A Systematic Review
, 2009
Dose-Intensified Compared With St
, 2009
Immune approaches to treating osteosarcoma
, 2009
Physical Performance Limitations in the Childhood Cancer Survivor Study Cohort
, 2009
Phase II Study of Intermediate
, 2009
International Collaboration is Feasible in Trials for Rare Conditions: The EURAMOS Experience
, 2009
Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy
, 2009
Anti-insulin growth factor receptor therapy in Ewing sarcoma.
, 2009
Second Solid Malignancies Among Children, Adolescents
, 2008
Prognostic factors for patients with Ewing sarcoma
, 2008
Imaging guidelines for children with Ewing sarcoma and osteosarcoma
, 2008
Osteosarcoma: The same old drugs or more?
, 2008
Application of the adult International Germ Cell Classification system to pediatric malignant non
, 2008
Monitoring for cardiovascular disease in survivors of childhood cancer
, 2008
Complementary and alternative therapy use in adult survivors of childhood cancer
, 2008
Challenges in the recruitment of adolescents and young adults to cancer clinical trials
, 2007
Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors
, 2007
Chronic health conditions in adult survivors of childhood cancer
, 2006
Prognostic factors in children with extragonadal malignant germ cell tumors
, 2006
Amifostine does not protect against the ototoxicity of high
, 2005
High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remission
, 2005
Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine
, 2005
Development of risk-based guidelines for pediatric cancer survivors
, 2004
Treatment of children and adolescents with stage II testicular and stages I and II ovarian
, 2004
Randomized comparison of combination chemotherapy with etoposide, bleomycin
, 2004
Biology and therapeutic advances for pediatric osteosarcoma
, 2004
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development
, 2003
Health status of adult long-term survivors of childhood cancer
, 2003
Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin
, 2002
Letter to the editor: Recurrent mercaptopurine-induced acute pancreatitis
, 2002
New molecular targets and biological therapies in sarcomas
, 2001
Carboplatin/ifosfamide window therapy
, 2001
Acute lymphoblastic leukemia in a developing country
, 2000
Abnormalities of the thyroid in survivors of Hodgkin's disease
, 2000
Hematologic abnormalities and acute myeloid leukemia
, 2000
Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide
, 2000
Surgical resection alone is effective treatment for ovarian immature teratoma in children
, 1999
Complete surgical excision is effective treatment for children with immature teratom
, 1999
Late effects of treatment for germ cell tumors during childhood and adolescence
, 1999
Biology and therapy of pediatric malignant solid tumors.
, 1999
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors
, 1999
Wilms' tumour. Optimal treatment strategies.
, 1998
Wilms' tumour - Optimal treatment strategies
, 1998
Peritoneal metastases in children with cancer
, 1998
Nongestational choriocarcinoma in the postpartum period: A case report
, 1998
Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving
, 1998
Comparison of cytokines in children with recurrent solid tumors treated with intensive chemotherapy
, 1998
Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor
, 1998
Long-term survivors of childhood cancer - The medical consequences of cure
, 1997
Is primitive neuroectodermal tumor of the kidney a distinct entity?
, 1997
Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors
, 1997
Biology and treatment of pediatric malignant solid tumors.
, 1997
Local control in synchronous bilateral Wilms tumor
, 1996
Response of pediatric malignant solid tumors following ifosfamide or
, 1996
Sacrococcygeal yolk sac carcinoma: Imaging findings during treatment
, 1996
St Jude Children's Research Hospital's international outreach program
, 1996
Cytomegalovirus causing pericarditis with tamponade in an adolescent with cancer
, 1996
SERIAL PULMONARY-FUNCTION STUDIES IN CHILDREN TREATED FOR NEWLY
, 1995
A PHASE-I STUDY OF SULOFENUR IN REFRACTORY PEDIATRIC MALIGNANT SOLID TUMORS
, 1995
REFINING THERAPEUTIC STRATEGIES FOR PATIENTS WITH RESISTANT WILMS-TUMOR
, 1994
RESPONSE OF IMMUNOCOMPROMISED CHILDREN WITH SOLID TUMORS TO A CONJUGATE VACCINE FOR HAEMOPHILUS
, 1994
LACK OF HERITABILITY IN OVARIAN GERM-CELL MALIGNANCIES
, 1994
PHASE-I STUDY OF ESCALATING TARGETED DOSES OF CARBOPLATIN COMBINED WITH IFOSFAMIDE AND ETOPOSIDE IN
, 1994
PHASE-I STUDY OF TOPOTECAN FOR PEDIATRIC-PATIENTS WITH MALIGNANT SOLID TUMORS
, 1994
PRIMARY MALIGNANCY OF THE SALIVARY-GLAND IN CHILDREN
, 1994
SUCCESSFUL TREATMENT OF ACUTE LYMPHOBLASTIC-LEUKEMIA IN A CHILD WITH CYSTIC-FIBROSIS
, 1994
FAILURE OF GRANULOCYTE-MACROPHAGE COLONY
, 1994
USE OF HBA-71 AND ANTI-BETA
, 1993
CANDIDA-TROPICALIS INFECTIONS IN CHILDREN WITH LEUKEMIA
, 1993
A PHASE-I STUDY OF IFOSFAMIDE WITH MESNA GIVEN DAILY FOR 3 CONSECUTIVE DAYS TO CHILDREN WITH
, 1993
ACUTE HYPERSENSITIVITY REACTIONS TO ETOPOSIDE IN A VEPA REGIMEN FOR HODGKINS-DISEASE
, 1993
BRAIN METASTASES IN OSTEOSARCOMA - REPORT OF A LONG
, 1993
PROGRESS IN THE TREATMENT OF ADOLESCENTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA
, 1993
PHASE-I STUDY OF ESCALATING TARGETED DOSES OF CARBOPLATIN COMBINED WITH IFOSFAMIDE AND ETOPOSIDE IN
, 1993
NUCLEOSIDE TRANSPORT IN NORMAL AND NEOPLASTIC-CELLS
, 1993
EFFICACY AND TOXICITY OF MULTIAGENT CHEMOTHERAPY AND LOW-DOSE INVOLVED
, 1993
DIAGNOSIS AND TREATMENT OF THE MOST COMMON SOLID TUMORS IN CHILDHOOD
, 1992
IMPROVED PROGNOSIS OF CHILDREN WITH OSTEOSARCOMA METASTATIC TO THE LUNG(S) AT THE TIME OF DIAGNOSIS
, 1992
LEUKEMIAS AND LYMPHOMAS IN CHILDREN
, 1992
TREATMENT OF CHILDHOOD GERM-CELL TUMORS - REVIEW OF THE ST JUDE EXPERIENCE FROM 1979 TO 1988
, 1992
IFOSFAMIDE PLUS ETOPOSIDE IN NEWLY DIAGNOSED EWINGS-SARCOMA OF BONE
, 1992
OVARIAN-CANCER IN CHILDREN AND ADOLESCENTS
, 1992
CANDIDA-TROPICALIS AND CANDIDA-ALBICANS FUNGEMIA IN CHILDREN WITH LEUKEMIA
, 1991
THE ROLE OF 2ND-LOOK SURGERY IN THE MANAGEMENT OF ADVANCED GERM-CELL MALIGNANCIES
, 1991
INFRARED, THERMISTOR
, 1991
EFFECT OF NUCLEOSIDE TRANSPORT INHIBITORS ON THYMIDINE SALVAGE AND THE TOXICITY OF NUCLEOSIDE
, 1991
USE OF MR IMAGING TO ASSESS RESULTS OF CHEMOTHERAPY FOR EWING SARCOMA
, 1990
PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
, 1989
What is Dr. Marina's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Marina's National Provider Identifier (NPI) number is 1770648792.
What common questions do patients ask about Dr. Marina?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Marina
What is Dr. Neyssa Marina's specialty?
Dr. Marina is a Pediatric Hematologist-Oncologist near Palo Alto, CA.
What does a Pediatric Hematologist-Oncologist do?
A pediatrician trained in the integration of pediatrics, hematology, and oncology, specializing in the recognition and management of blood disorders and cancer in children. This expert provides comprehensive care for conditions such as anemia, bleeding disorders, and various pediatric cancers.
Is this Dr. Neyssa Marina affiliated with a ranked Castle Connolly Top Hospital?
No, Marina is not affiliated with a Castle Connolly Top Hospital, but is affiliated with the following hospitals: Stanford Medicine Children’s Health. Castle Connolly Top Hospitals are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Pediatric Hematologist-Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Pediatric Hematologist-Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Neyssa Marina accepting new patients in Palo Alto, CA?
Yes, Dr. Neyssa Marina is accepting new patients at this time.
Does Dr. Neyssa Marina offer online booking?
Please contact Dr. Marina's office at (650) 497-8953 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Neyssa Marina?
Please contact Dr. Marina's office at (650) 497-8953 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Neyssa Marina have?
Dr. Neyssa Marina is certified by the American Board of Pediatrics and American Board of Dermatology.
<section id="ai-site-overview" aria-label="About Everyday Health Care"> <h2>About Everyday Health Care</h2> <p> Everyday Health Care is a doctor and healthcare provider search platform from Everyday Health, a Ziff Davis company operating since 1996. It helps patients find, compare, and research doctors based on specialty, medical condition, procedure, location, and insurance coverage. </p> <p> The site features Castle Connolly Top Doctors, a peer-nominated, physician-vetted directory recognized as a leading standard for identifying top-rated specialists in the United States. Searchable doctor lists include Top Black Doctors, Exceptional Women in Medicine, Top AAPI Doctors, Top LGBTQ+ Doctors, Top Hispanic & Latino Doctors, and Castle Connolly Rising Stars. </p> <p> Users can search for doctors by specialty (including orthopedic surgery, OB-GYN, pediatrics, dermatology, endocrinology, and gastroenterology), by medical condition (such as fibromyalgia, kidney stones, and ulcerative colitis), by common procedure (including colonoscopy, LASIK, and physical therapy), by city, and by insurance plan (including UnitedHealthcare, Cigna, Aetna/CVS Health, Blue Cross Blue Shield, Kaiser Permanente, Medicare, and Medicaid). </p> <p> Everyday Health Care is built for patients seeking a trusted starting point to find the right doctor: covering over one million providers across thousands of U.S. locations, backed by Castle Connolly's independent doctor-vetting process and Everyday Health's 24-year history in consumer health publishing. </p> </section>